The overall objective of the current SCOR and the proposed renewal is to elucidate the molecular genetics and biology of cardiac hypertrophy and dilatation, two common responses of the heart to any form of injury. The overall objectives of this project are to determine whether switching off expression of the mutant sarcomeric protein or inhibiting the renin angiotensin system (RAS) can prevent, attenuate, or reverse the excessive interstitial collagen, myocyte disarray, and cardiac dysfunction, and to identify the trophic factors that mediate the cardiac phenotype in familial hypertrophic cardiomyopathy (FHCM). Mutations in genes coding for sarcomeric proteins including the cardiac troponin T (cTnT) cause FHCM, a disease characterized clinically by sudden cardiac death (SCD) and heart failure and pathologically by cardiac myocyte hypertrophy, disarray, and excessive interstitial collagen. The research emphasis now is to elucidate the pathogenesis of FHCM, and explore the impact of specific interventions to prevent, attenuate, or reverse the phenotype. In pursuit of these goals, we have expressed the mutant cTnT-Gln/92 protein, known to cause FHCM in man, in the heart of transgenic mouse and developed a model that exhibits excessive interstitial collagen, myocyte disarray, and cardiac dysfunction. Cardiac dysfunction precedes the development of myocyte disarray and excessive interstitial collagen, a funding that confirms our results in cultured cardiac myocytes. Therefore, we proposed that a """"""""primary"""""""" defect in FHCM is impaired myocyte contractility leading to activation of known [such as angiotensin II (AT)] and novel growth factors, which play a fundamental role in inducing the """"""""secondary"""""""" cardiac phenotypes (excessive interstitial collagen, myocyte hypertrophy, and disarray). To test this hypothesis, we will determine whether inhibiting the RAS can prevent, attenuate, or reverse the observed cardiac phenotype. To determine the reversibility of FHCM phenotype, we will generate an inducible transgenic mouse model and then switch off expression of the mutant cTnT-Gln/92 protein and characterize the reversal of excessive interstitial collagen, myocyte disarray, and cardiac dysfunction. To identify the novel and novel trophic factors, we will perform expression-monitoring utilizing DNA microarray chips and subtraction hybridization. To characterize the role of the myocytes, utilizing recombinant adenoviruses, and determine their impact on collagen synthesis, myocyte structure and function. The results of these experiments are expected to provide fundamental insights into the pathogenesis of FHCM that could lead to new therapeutic or preventive modalities for FHCM.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL054313-06
Application #
6316438
Study Section
Special Emphasis Panel (ZHL1-CSR-Y (O1))
Project Start
1995-02-17
Project End
2005-01-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
$184,963
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Nassif, Michael E; LaRue, Shane J; Raymer, David S et al. (2016) Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circ Heart Fail 9:
Adamo, Luigi; Nassif, Michael; Tibrewala, Anjan et al. (2015) The Heartmate Risk Score predicts morbidity and mortality in unselected left ventricular assist device recipients and risk stratifies INTERMACS class 1 patients. JACC Heart Fail 3:283-90
Nassif, Michael E; Patel, Jayendrakumar S; Shuster, Jerrica E et al. (2015) Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail 3:146-53
Mann, Douglas L; Mochly-Rosen, Daria (2013) Translational medicine: mitigating risks for investigators. Nat Rev Drug Discov 12:327-8
Lombardi, Raffaella; Rodriguez, Gabriela; Chen, Suet Nee et al. (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119:1398-407
Daw, E W; Lu, Y; Marian, A J et al. (2008) Identifying modifier loci in existing genome scan data. Ann Hum Genet 72:670-5
Marian, Ali J (2008) Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol 23:199-205
Lombardi, Raffaella; Bell, Achim; Senthil, Vinitha et al. (2008) Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res 79:109-17
Mann, Douglas L; Bozkurt, Biykem; Torre-Amione, Guillermo et al. (2008) Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci 1:142-5
Daw, E Warwick; Chen, Suet Nee; Czernuszewicz, Grazyna et al. (2007) Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet 16:2463-71

Showing the most recent 10 out of 69 publications